Literature DB >> 26217986

Optimal fractionation in radiotherapy for non-small cell lung cancer--a modelling approach.

Emely Lindblom1, Alexandru Dasu2, Iuliana Toma-Dasu1,3.   

Abstract

BACKGROUND: Conventionally fractionated radiotherapy (CFRT) has proven ineffective in treating non-small cell lung cancer while more promising results have been obtained with stereotactic body radiotherapy (SBRT). Hypoxic tumours, however, might present a challenge to extremely hypofractionated schedules due to the decreased possibility for inter-fraction fast reoxygenation. A potentially successful compromise might be found in schedules employing several fractions of varying fractional doses. In this modelling study, a wide range of fractionation schedules from single-fraction treatments to heterogeneous, multifraction schedules taking into account repair, repopulation, reoxygenation and radiosensitivity of the tumour cells, has been explored with respect to the probability of controlling lung tumours.
MATERIAL AND METHODS: The response to radiation of tumours with heterogeneous spatial and temporal oxygenation was simulated including the effects of accelerated repopulation and intra-fraction repair. Various treatments with respect to time, dose and fractionation were considered and the outcome was estimated as Poisson-based tumour control probability for local control.
RESULTS: For well oxygenated tumours, heterogeneous fractionation could increase local control while hypoxic tumours are not efficiently targeted by such treatments despite reoxygenation. For hypofractionated treatments employing large doses per fraction, a synergistic effect was observed between intra-fraction repair and inter-fraction fast reoxygenation of the hypoxic cells as demonstrated by a reduction in D50 from 53.3 Gy for 2 fractions to 52.7 Gy for 5 fractions.
CONCLUSIONS: For well oxygenated tumours, heterogeneous fractionation schedules could increase local control rates substantially compared to CFRT. For hypoxic tumours, SBRT-like hypofractionated schedules might be optimal despite the increased risk of intra-fraction repair due to a synergistic effect with inter-fraction reoxygenation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26217986     DOI: 10.3109/0284186X.2015.1061207

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

1.  Radiation-induced Vascular Damage and the Impact on the Treatment Outcome of Stereotactic Body Radiotherapy.

Authors:  Emely Kjellsson Lindblom; Susanta Hui; Jamison Brooks; Alexandru Dasu; Maciej Kujawski; Iuliana Toma-Dasu
Journal:  Anticancer Res       Date:  2019-06       Impact factor: 2.480

2.  Bioinformatics Analysis for Identifying Differentially Expressed MicroRNAs Derived from Plasma Exosomes Associated with Radiotherapy Resistance in Non-Small-Cell Lung Cancer.

Authors:  Lirong Zeng; Guilin Zeng; Zhong Ye
Journal:  Appl Bionics Biomech       Date:  2022-05-31       Impact factor: 1.664

Review 3.  Radiobiological Optimization in Lung Stereotactic Body Radiation Therapy: Are We Ready to Apply Radiobiological Models?

Authors:  Marco D'Andrea; Silvia Strolin; Sara Ungania; Alessandra Cacciatore; Vicente Bruzzaniti; Raffaella Marconi; Marcello Benassi; Lidia Strigari
Journal:  Front Oncol       Date:  2018-01-08       Impact factor: 6.244

4.  Treating Glioblastoma Multiforme (GBM) with super hyperfractionated radiation therapy: Implication of temporal dose fractionation optimization including cancer stem cell dynamics.

Authors:  Victoria Y Yu; Dan Nguyen; Daniel O'Connor; Dan Ruan; Tania Kaprealian; Robert Chin; Ke Sheng
Journal:  PLoS One       Date:  2021-02-01       Impact factor: 3.240

5.  Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.

Authors:  Xu Chen; Yanmei Xu; Xingyun Liao; Rongxia Liao; Luping Zhang; Kai Niu; Tao Li; Dezhi Li; Zhengtang Chen; Yuzhong Duan; Jianguo Sun
Journal:  Tumour Biol       Date:  2016-04-13

6.  Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.

Authors:  Bao-Tian Huang; Zhu Lin; Pei-Xian Lin; Jia-Yang Lu; Chuang-Zhen Chen
Journal:  Oncotarget       Date:  2016-06-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.